The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of (a) this document is only for the purpose of providing information about the Company to the public in Hong Kong and ...

Core Viewpoint - Novo Nordisk's shares have dropped by 52% over the past year, presenting a potential buying opportunity for investors due to its strong market position and growth prospects in diabetes and weight management treatments [1][4]. Company Overview - Novo Nordisk is a leader in developing diabetes treatments, holding a 33.3% market share in this sector as of February [2]. - The company has a long history of attracting top talent and consistently innovating in diabetes care [2]. Recent Challenges - The significant drop in share price is attributed to disappointing financial results and clinical progress, which did not meet the high expectations set by the company's valuation metrics [4]. - Despite reporting effective phase 3 results for CagriSema, an investigational weight management drug, the results fell short of management's expectations, leading to investor dissatisfaction [5]. Pipeline and Growth Potential - Novo Nordisk's pipeline remains robust, with several promising candidates in development, including Amycretin, which is in late-stage studies [6]. - The company is also diversifying its portfolio by developing treatments for rare diseases and neurological disorders, which could enhance its long-term growth prospects [8]. Financial Performance - In the first quarter, net sales grew by 19% year over year to 78.1 billion Danish krone ($12.1 billion), and net profit increased by 14% year over year to $4.5 billion [9]. - The forward price-to-earnings (P/E) ratio has decreased to 16.9, which is slightly above the healthcare industry's average of 16.2 and lower than the S&P 500's 22.3 [10]. Future Outlook - The company is expected to make significant clinical and regulatory progress, potentially launching blockbuster medications in the next six years [13]. - Continued strong financial results and dividend increases are anticipated, with a compound annual growth rate of 12.2% needed for the stock to double in value over the next six years [14].

Core Insights - The weight management medicines market is experiencing significant growth, with Eli Lilly positioned to dominate through the end of the decade due to its strong pipeline and clinical successes [1][9] - Eli Lilly's primary competitor in this space is Novo Nordisk, with both companies having deep pipelines and successful products [2][4] Group 1: Competitive Landscape - Eli Lilly's tirzepatide has shown superior efficacy compared to Novo Nordisk's semaglutide in clinical trials [5] - Novo Nordisk's next-generation medicine, CagriSema, achieved a mean weight loss of 22.7% after 68 weeks, falling short of its 25% target, which may hinder its commercial success [6][5] - Eli Lilly has additional promising candidates, including orforglipron and retatrutide, which could further enhance its competitive edge [7] Group 2: Strategic Moves - Eli Lilly is partnering with Camurus to utilize FluidCrystal technology for long-acting delivery of injectable therapies, addressing the issue of weight regain after discontinuation of medications [8] Group 3: Financial Performance - Eli Lilly reported a 45% year-over-year revenue increase to $12.7 billion and a 29% increase in net income to $3 billion in the first quarter [11] - Despite a higher forward price-to-earnings (P/E) ratio of 35.3 compared to the healthcare industry's average of 15.9, Eli Lilly's growth justifies the premium [11] Group 4: Investment Outlook - Eli Lilly is not solely focused on diabetes or weight loss, as it has also developed breakthrough medicines in other therapeutic areas, including Alzheimer's disease [10] - The company's strong financial results and promising pipeline make its stock an attractive long-term investment [12]

Core Viewpoint - Hims & Hers Health, Inc. has introduced a new affordable pricing model for six months of prescription-only Wegovy, aiming to enhance accessibility to obesity care for Americans, which is expected to significantly boost the company's business [1][7]. Company Developments - Following the announcement of the new pricing model, Hims & Hers shares experienced a decline of nearly 8% [2]. - The company currently has a market capitalization of $11.94 billion and reported an earnings yield of 1.4%, which is favorable compared to the industry's negative yield. In the last quarter, Hims & Hers achieved an earnings surprise of 66.7% [3]. - Effective May 22, 2025, new customers can access Wegovy for $549 per month for six months, which includes a holistic approach to weight loss powered by technology [4]. - Hims & Hers plans to continue offering a wide range of weight loss treatment options, including other medications and clinically-backed care plans [5]. - The company recently reported strong improvements in both top and bottom lines for the first quarter of 2025, with an increase in subscribers and monthly online revenue per average subscriber [8]. Industry Prospects - The global weight management market was valued at $329.83 billion in 2024 and is projected to reach $488.42 billion by 2032, growing at a CAGR of approximately 5%. This growth is driven by rising obesity rates and the adoption of personalized healthcare solutions [6]. - The latest product availability is seen as a significant milestone for Hims & Hers, expected to enhance its business prospects [7].

Financial Data and Key Metrics Changes - Revenue for Q4 2024 totaled $184 million, down 10% year-over-year, reflecting continued headwinds in digital and workshop businesses and the closure of the consumer products business [55][48] - Full year 2024 revenue was $786 million, a decline of 12% compared to the prior year, but above prior guidance of at least $770 million [48] - Adjusted gross margin was 69.1% in Q4, up from 61.4% in the prior year, driven by cost actions and the closure of the lower gross margin consumer products business [55][50] - Adjusted EBITDA margin was 27.4% in Q4, the highest level since Q3 2022 [40][50] Business Line Data and Key Metrics Changes - Behavioral business revenue declined 12% year-over-year, while clinical business revenue grew by 58% [11] - Clinical subscribers ended the year at 92,000, growing 18% from Q3 and 38% year-over-year [48] - Subscription revenue overall was down 7% in Q4, but the overall rate per paid week increased sequentially due to a higher mix of clinical subscribers [49] Market Data and Key Metrics Changes - The company entered 2025 with a revenue headwind of approximately $45 million, driven by a lower 2024 ending subscriber base [14] - The clinical business is expected to continue strong growth in January and February, despite potential volatility due to uncertainties surrounding compounded semaglutide [59] Company Strategy and Development Direction - The company is focused on stabilization, recovery, and rebuilding to lay the groundwork for sustained future growth [15][41] - Plans to remove $100 million in run rate costs by the end of 2025, with the majority already actioned [15][38] - Emphasis on improving the end-to-end member experience and integrating clinical and behavioral offerings [17][20] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by existing capital structure and the need for investments to drive growth [16][42] - The company is committed to providing medication access in compliance with laws and regulations, while monitoring the impact of FDA decisions on medication supply [32][30] - Management expressed confidence in the long-term potential of the weight loss medication market and the company's unique competitive position [15][33] Other Important Information - The company ended 2024 with $53 million in cash and cash equivalents, with cash flow from operations being positive when excluding one-time restructuring payments and interest payments [51][54] - The company has engaged strategic advisers to assess its capital structure strategy moving forward [43] Q&A Session Summary Question: Trends during peak season and marketing environment - Management noted challenges in the behavioral business but saw encouraging trends in clinical growth and product engagement [66][70] Question: Importance of clinical subscriber growth and GLP-1 medications - Management highlighted the positive impact of compounding on clinical metrics and the expectation of a return to branded medication supply [78][82] Question: Avoiding a downward cycle with fewer subscribers - Management emphasized the value proposition of WeightWatchers and the need for innovation and product improvements to regain growth [90][92] Question: Subscriber levels needed for cash flow - Management indicated that while subscriber counts are challenged, the increase in average revenue per user (ARPU) is encouraging [100][102] Question: Outcomes based on compounded semaglutide sales - Management expressed confidence in returning to branded medications as supply improves and highlighted ongoing evaluations of medication options [106][112]